Quebec-based Confab Laboratories has successfully undergone its second FDA audit for the manufacture and supply of pharmaceutical products to the U.S. The audit was a preapproval inspection for three drug products and demonstrated the company’s conformity to cGMP. Confab’s main focus is to provide manufacturing solutions for nonsterile conventional dosage forms with an efficient turnaround. Confab’s chief executive officer, Guy Lamarre, commented, “The future looked bright...